News

The death will likely further stoke safety concerns around Sarepta's gene therapies, as well as raise questions around the ...
According to multiple reports, a 51-year-old man with limb-girdle muscular dystrophy died from acute liver failure after ...
Shares of Sarepta Therapeutics (NASDAQ: SRPT) plunged 26.85% in Friday pre-market after a clinical trial participant died ...
Shares of Sarepta Therapeutics plummeted nearly 30% premarket Friday following a report that a third patient has died during ...
These were the most active stocks ahead of Friday's market open: Sarepta Therapeutics Inc.'s stock tumbled 27% after the company said another patient died following gene-therapy treatment, Bloomberg ...
The pharma company said it would lay off a third of its workforce and add a black-box warning to its controversial gene ...
The drastic cost-cutting move follows the deaths of two teenagers that forced the company to restrict usage of its gene ...